# Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142
Canonical URL: https://biopharmsignal.com/news/EBS/emergent-biosolutions-secures-long-term-strategic-manufacturing-contract-with-sab-biotherapeutics-to-advance-type-1-diabetes-candidate-sab-142
Ticker: EBS
Company: Emergent BioSolutions
Source: Emergent BioSolutions
Published: 2026-04-29 11:35 EST
Original Source URL: https://investors.emergentbiosolutions.com
## Summary

GAITHERSBURG, Md., April 29, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a multi-year agreement with SAB Biotherapeutics, Inc. (Nasdaq: SABS, SAB BIO) to support the process development and manufacturing of SAB-142, SAB BIO’s lead program in clinical development

## Article Body
GAITHERSBURG, Md., April 29, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a multi-year agreement with SAB Biotherapeutics, Inc. (Nasdaq: SABS, SAB BIO) to support the process development and manufacturing of SAB-142, SAB BIO’s lead program in clinical development
## Recent Company News
- 2026-05-28 20:01 EST — [Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy](https://biopharmsignal.com/news/EBS/emergent-biosolutions-receives-64-5-million-contract-modification-for-batr-botulism-antitoxin-heptavalent-a-b-c-d-e-f-g-equine-to-support-u-s-biodefense-strategy) — Source: Emergent BioSolutions
- 2026-05-20 11:30 EST — [Emergent BioSolutions to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/EBS/emergent-biosolutions-to-participate-in-upcoming-investor-conferences) — Source: Emergent BioSolutions
- 2026-05-18 12:59 EST — [Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]](https://biopharmsignal.com/news/EBS/emergent-biosolutions-receives-saudi-food-and-drug-authority-approval-for-acam2000r-smallpox-and-mpox-vaccinia-vaccine-live) — Source: Emergent BioSolutions
- 2026-04-30 20:30 EST — [Emergent BioSolutions Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/EBS/emergent-biosolutions-reports-first-quarter-2026-financial-results) — Source: Emergent BioSolutions
- 2026-04-30 11:55 EST — [Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox](https://biopharmsignal.com/news/EBS/emergent-biosolutions-receives-approval-from-singapore-health-sciences-authority-for-expanded-indication-of-acam2000r-smallpox-and-mpox-vaccinia-vaccine-live-to-include-mpox) — Source: Emergent BioSolutions
## Related News
- 2026-07-22 20:05 EST — AZTA — [Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast](https://biopharmsignal.com/news/AZTA/azenta-announces-fiscal-2026-third-quarter-conference-call-and-webcast-48419fff)
- 2026-07-22 20:05 EST — VKTX — [Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2026-on-july--bbf2553f)
- 2026-07-22 20:01 EST — AXON — [Axon to Release Second Quarter 2026 Earnings on August 5, 2026](https://biopharmsignal.com/news/AXON/axon-to-release-second-quarter-2026-earnings-on-august-5-2026-66120902)
- 2026-07-22 12:39 EST — ARTL — [New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition](https://biopharmsignal.com/news/ARTL/new-analysis-of-over-50-studies-showed-that-all-the-non-prescription-cbd-product-a3445432)
- 2026-07-22 12:30 EST — NRSN — [NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS](https://biopharmsignal.com/news/NRSN/neurosense-advances-primec-toward-new-drug-submission-to-health-canada-for-als-721c198c)